A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs FPX01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Fusion Pharmaceuticals
- 04 Jun 2019 Trial design of this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2019 According to a Fusion Pharmaceuticals media release , data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4.
- 19 Feb 2019 According to a Fusion Pharmaceuticals media release, first patient was dosed.